Enzon’s HIF-1 Alpha Antagonist Shows Antitumor Activity

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) presented data from its pipeline programs at the 2008 EORTC-NCI-AACR (European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research) annual meeting in Geneva, Switzerland.

More: continued here

Filed under: Cancer on October 29th, 2008